Back to Search
Start Over
Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
- Source :
- Pathogens; Oct2021, Vol. 10 Issue 10, p1253-1253, 1p
- Publication Year :
- 2021
-
Abstract
- Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20760817
- Volume :
- 10
- Issue :
- 10
- Database :
- Complementary Index
- Journal :
- Pathogens
- Publication Type :
- Academic Journal
- Accession number :
- 153341306
- Full Text :
- https://doi.org/10.3390/pathogens10101253